Implementation of all oral 24 weeks regimen for DR-TB patients

Locations

Belarus, Tajikistan, Uzbekistan
Topics

AMR, Tuberculosis
Methodology

Observational study
Reference

OCA021-21
Views

740
Downloaded

12

Purpose of study

New all-oral shorter MDR/RR-TB treatment regimens can be used by national TB programmes under operational research conditions. The BPaML regimen has been shown to be safe and effective in the PRACTECAL clinical trial. This study proposal is for a ...

Study status

Concept
Protocol & ERB
Implementation
Completion
Archived

Study timeline

Documents

Study_concept_paper_PRACTECAL_OR.docx 60 KB
Research_Committee_Feedback_PRACTECAL_OR.pdf 113 KB
MSF_ERB_2180_ethics_approval_08Dec2021.pdf 168 KB
MSF_ERB_2180a_ethics_approval_08Dec2021.pdf 120 KB
MSF_ERB_2180b_ethics_approval_26Jan22.pdf 119 KB
MSF_ERB_2180c_ethics_approval_26Jan22.pdf 120 KB
SMARRTT_Protocol_v1.2_of_07Dec2021.docx 969 KB
SMARRTT_Tajikistan_v1.1_of_01Dec2021.docx 135 KB
SMARRTT_Belarus_v1.1_24Jan2022.docx 142 KB
SMARRTT_Uzbekistan_v1.1_24Jan2022.docx 162 KB
920-local-ethics-approval-2022-02-14.pdf 509 KB
920-abstract-2024-03-20.docx 24.4 KB
920-local-ethics-approval-2024-03-27.docx 13.5 KB
920-publication-2024-07-01.pdf 117 KB
920-publication-2024-07-01.pdf 807 KB
920-publication-2025-02-18.pdf 549 KB

Publications

The Effectiveness and Safety of Bedaquiline, Pretomanid, and Linezolid (BPaL)–Based Regimens for Rifampicin-Resistant Tuberculosis in Non-Trial Settings—A Prospective Cohort Study in Belarus and Uzbekistan

Animesh Sinha "–" Clinical Infectious Diseases "(2025)"

Previous study

Next study